SEC Comment Letter 0000000000-23-005175 to bluebird bio, Inc. (BLUE) (CIK 0001293971)
bluebird bio, Inc. (BLUE) (CIK 0001293971)
Date: May 15, 2023 · CIK: 0001293971 · Accession: 0000000000-23-005175
AI Filing Summary & Sentiment
File numbers found in text: 333-271772
Letter
United States securities and exchange commission logo May 15, 2023 Andrew Obenshain President and Chief Executive Officer bluebird bio, Inc. 455 Grand Union Boulevard Somerville, MA 02145 Re:bluebird bio, Inc. Registration Statement on Form S-3 Filed May 9, 2023 File No. 333-271772 Dear Andrew Obenshain: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Wesley C. Holmes, Esq.
Show Raw Text
United States securities and exchange commission logo
May 15, 2023
Andrew Obenshain
President and Chief Executive Officer
bluebird bio, Inc.
455 Grand Union Boulevard
Somerville, MA 02145
Re:bluebird bio, Inc.
Registration Statement on Form S-3
Filed May 9, 2023
File No. 333-271772
Dear Andrew Obenshain:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Wesley C. Holmes, Esq.